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Background/Aims
The aim of this study was to evaluate the efficacy and cost efficiency of omeprazole 10 mg and rabeprazole 10 mg once daily 
for 24 weeks in the maintenance therapy.
Methods
This was a randomized, open-label study enrolling 279 patients with erosive esophagitis A or B (Los Angeles classification) and 
typical gastroesophageal reflux disease symptoms. Patients who showed complete endoscopic and symptomatic healing after 
8 weeks of proton pump inhibitor treatment were randomly allocated to maintenance treatment with omeprazole 10 mg once 
daily or rabeprazole 10 mg once daily for 42 weeks. The primary efficacy endpoint was the proportion of patients with symp-
tomatic remission at 42 weeks. 
Results
At the end of 42 weeks of maintenance therapy, 96.4% of omeprazole and 95.1% of rabeprazole treated patients remained 
symptom free (P ＞ 0.05). Two drugs were also comparable with regard to the severity and frequency of reflux symptoms dur-
ing the maintenance phase (P ＞ 0.05). By the cost-minimization analysis, the mean total costs per patient for remaining 
symptom-free for 6 months were 241,775 won for omeprazole and 287,115 won for rabeprazole, respectively.
Conclusions
Omeprazole 10 mg appeared to have similar efficacy in maintaining symptomatic remission as rabeprazole 10 mg, but was 
superior to rabeprazole 10 mg in terms of cost efficiency in the maintenance therapy of gastroesophageal reflux disease symp-
toms.
(J Neurogastroenterol Motil 2013;19:219-226)
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Introduction
Gastroesophageal reflux disease (GERD) is a major public 
health problem in Korea. GERD affects approximately 3.4-3.8% 
of the Korean population1,2 and its incidence is on the increase. 
Generally, treatment of GERD begins with suppression of acid 
secretion by proton pump inhibitors (PPIs). PPI therapy re-
lieved symptoms and healed the esophagitis in more than 80% of 
patients within 8 weeks of treatment,3 and it was better than pla-
cebo and histamine 2 receptor antagonist therapy as the treatment 
for esophagitis at 4-8 weeks.4 However, due to the recurring na-
ture of GERD, most patients require additional long-term main-
tenance therapy.
Management options for the long-term management of 
GERD are either daily therapy or on-demand therapy of PPI. 
On-demand therapy is an adequate option for patients with 
non-erosive reflux disease (NERD) and uninvestigated GERD 
without alarm features.5-8 In contrast,  continuous treatment is ef-
fective in the maintenance of healing in patients with esophagitis.9 
And also, continuous treatment was preferred over on-demand 
therapy in patients with esophagitis, in the elderly10 and in pa-
tients with Barrett’s esophagus11 since on-demand treatment is 
less cost-saving in patients with esophagitis and symptomatic re-
lapses occur frequently in severe grades. 
Continuous PPI therapy for reflux esophagitis is associated 
with a large economic burden. Therefore, it is important to use 
the most cost effective PPIs at the adequate dose. Omeprazole is 
the oldest PPI approved for clinical use in the treatment and pre-
vention of reflux esophagitis.12,13 Although new PPIs have been 
developed since, omeprazole 20 mg is still as effective as the new 
PPIs including rabeprazole 20 mg, lansoprazole 30 mg and pan-
toprazole 40 mg in the acute treatment of reflux esophagitis and 
prevention of the relapse of esophagitis.14-17
In terms of half dose omeprazole, maintenance treatment 
with omeprazole 10 mg daily keeps about 60% of patients with 
erosive esophagitis free of relapse18 and half dose omeprazole was 
recommended in the prevention of relapse of esophagitis.19 
However, little information is available about its effectiveness 
compared with other newer half dose PPI drugs in continuous 
PPI therapy for reflux esophagitis. 
Therefore, in this study, we tried to determine the efficacy and 
cost effectiveness of maintenance therapy with omeprazole 10 mg 
compared with rabeprazole 10 mg in patients with reflux esoph-
agitis who experienced symptom resolution after an 8 week course 
of continuous omeprazole therapy.
Materials and Methods
Patients
Subjects with typical GERD symptoms such as heartburn, 
regurgitation or epigastric pain for 2 days or more during the last 
7 days were enrolled in the healing phase of the trial if they met 
the following eligibility criteria: were 18 to 75 years of age with a 
history of reflux symptoms for 6 months or longer, and had endo-
scopically proven erosive esophagitis (Grade A or B using Los 
Angeles [LA] classification of esophagitis). All participants ei-
ther underwent esophagogastroduodenoscopy (EGD) at base-
line, or had undergone EGD within 2 weeks prior to enrollment. 
Exclusion criteria were as follows: endoscopically proven Grade 
C or D esophagitis; presence of another organic lesion on endos-
copy such as peptic ulcer or Barrett’s esophagus; past history of 
gastric or esophageal surgery; signs of gastrointestinal bleeding at 
the time of EGD; chronic alcoholism (＞ 40 g alcohol/day); 
heavy smoking (＞ 2 packs/day); pregnancy or lactation; pres-
ence of abnormal liver function test (＞ 2× normal AST and 
ALT); known hypersensitivity to any component of omeprazole 
or rabeprazole; and concomitant diseases that might affect the re-
sults such as epilepsy or manic-depressive disorder. Patients were 
also excluded if they had received PPI or histamine 2 blocker 
therapy within 15 days before the screening date, or had received 
other medications that might affect the interpretation of the treat-
ment outcome (quinidine, high dose corticosteroid, nonsteroidal 
anti-inflammatory, wafarin, anticholinergic, prostaglandin ana-
logue or salicylate [except low dose aspirin]). 
Study Design
This was a multi-center, randomized, double blinded, non- 
inferiority study consisting of a healing phase and a maintenance 
phase (Fig. 1). All patients received open-label oral omeprazole 
20 mg once daily for 8 weeks. Repeat EGD was performed at the 
end of 8 weeks. This study was undertaken according to the prin-
ciples of the Declaration of Helsinki and local ethics committee 
approval was obtained before the start of the study. Patients 
whose esophagitis was healed and were asymptomatic started 
maintenance treatment with omeprazole 10 mg q.d. or rabepra-
zole 10 mg q.d. for 24 weeks. ‘Healing’ was defined as no macro-
scopic mucosal breaks based on the LA classification, and ‘asymp-
tomatic’ was defined as having complete resolution of reflux 
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Figure 1. Study design.
symptoms (defined as no reflux symptoms during the last 7 days 
prior to the visit) or relief of reflux symptoms (defined as no more 
than 1 day with a mild episode of reflux symptom during the last 
7 days prior to the visit). Those who were not healed or were 
symptomatic at the end of the healing phase were not considered 
for maintenance therapy.
Maintenance treatment continued for 24 weeks. Patients 
were instructed to visit the outpatient clinic every month to re-
ceive drugs and report their symptoms and fill out the quality of 
life (QOL) questionnaire, the Korean version of EuroQol 5 di-
mensions (KEQ-5D). The occurrence and severity of GERD 
symptoms during the previous week were recorded using a 
questionnaire. Symptomatic relapse during the maintenance 
phase was defined as no more than 1 day of mild reflux symptoms 
(heartburn, acid regurgitation or epigastric pain) or moderate to 
severe reflux symptoms during the 1 week prior to visit. Severity 
of GERD symptoms was assessed as 0 = none; 1 = mild 
(present but causing little or no discomfort and can be ignored 
when not thought about); 2 = moderate (causes discomfort and 
some interference with daily routine); and 3 = severe (disabling 
and interferes considerably with the daily routine). KEQ-5D 
consists of 5 dimensions: mobility, self-care, usual activities, pain/ 
discomfort and anxiety/depression. The reason why KEQ-5D 
was used here is that it was recently validated for QOL in 
Koreans.20 It is mainly used for calculating quality-adjusted life 
years in pharmacoeconomic studies.21
Laboratory tests, including complete blood count, clinical 
chemistry, urinalysis, and pregnancy test (for female subjects 
with reproductive potential) were performed at the screening and 
at the end of the maintenance phase. In addition to the screening 
endoscopy, patients underwent endoscopy at the end of the heal-
ing phase and at the end of the maintenance phase. Assessments 
of adverse events were performed during all visits and were grad-
ed in terms of severity and relationship to the study drug. 
Efficacy and Cost Effectiveness Assessment
The primary aim of the study was to evaluate the resolution 
rates of GERD symptoms after 6 months of maintenance treat-
ment with omeprazole 10 mg q.d. and rabeprazole 10 mg q.d., 
and to compare them. Secondary efficacy variables included 
changes in the severity and frequency of symptoms, recurrence 
rates of esophagitis at the end of maintenance phase, and im-
provement in the QOL. The main safety outcome was the occur-
rence of adverse events and cost effectiveness during the main-
tenance phase. For the evaluation of cost effectiveness in this 
study, a cost minimization study was the appropriate form of eco-
nomic analysis, since utility gains were comparable for omepra-
zole 10 mg and rabeprazole 10 mg.3,22 
Costs were classified into direct and indirect costs. Direct 
costs consisted of payments for outpatient services and diagnostic 
tests such as endoscopy and medications. Indirect costs referred 
to transportation. Data on the direct and indirect costs were cal-
culated for each patient during 6 months after randomization, 
and an average cost for each item was estimated based on in-
formation from the National Health Insurance Corporation, do-
mestic and foreign pharmacoeconomic journals and Statistics 
Korea. In addition, decision tree sensitivity analyses were per-
formed to judge the robustness of the conclusions made with the 
various cost assumptions. A decision tree model for 1 year was 
developed to simulate possible treatment modalities for 6 months 
after maintenance treatment of GERD (Fig. 2). Recurrence rates 
and proportion of actual treatment modality assignment were 
based on the study conducted in Korea.23
Statistical Methods 
Efficacy of omeprazole was assessed as not inferior to that of 
rabeprazole in GERD patients. The predefined non-inferiority 
margin was an absolute difference of 20% in the primary end-
point between two groups. To test for non-inferiority with a back-
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Figure 2. Decision tree for management
plans after 6 months maintenance thera-
py for gastroesophageal reflux disease. 
PPI, proton pump inhibitor.
Figure 3. Flowchart of patient management in the study.
ground remission rate of 62-82%13,18,19 at 6 months by half dose 
omeprazole maintenance treatment with absolute non-inferiority 
margin of 20%, a total sample size of 92 patients was calculated 
for 80% power at a 5% significance level. Analysis was performed 
for the intention-to-treat (ITT) population, which included all 
patients who had received at least one dose of the study medica-
tion. The primary efficacy analysis was a comparison of the per-
centage of patients who remained healed (resolution rates) be-
tween the 2 maintenance treatment groups, using a Chi-square 
test or Fisher’s exact test. Secondary endpoints were also analyzed 
on the ITT population. Difference of symptom severity (expre-
ssed on a 4-point scale), frequency and recurrence rates of reflux 
esophagitis between the 2 groups were analyzed with a Chi- 
square test or Fisher’s exact test.
Results
Patient Disposition
A total of 239 patients received acute treatment. At the end of 
the acute treatment phase, only 165 patients experienced com-
plete resolution of reflux symptoms and erosive esophagitis and 
qualified for randomization in the maintenance treatment phase. 
All 165 patients who entered the maintenance treatment were in-
cluded in the ITT analyses. Of these patients, 83 were randomly 
assigned to receive omeprazole 10 mg once daily and 82 assigned 
to receive rabeprazole 10 mg once daily for 6 months (Fig. 3). 
Within the ITT population, there were no significant differences 
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Table 1. Demographic Characteristics
Characteristic
Omeprazole 
(n = 83)
Rabeprazole
(n = 82)
Age (mean ± SD, yr) 47.8 ± 12.8 47.2 ± 12.9
Gender (M/F) 57/26 59/23
Body weight (mean ± SD, kg) 68.2 ± 11.7 66.1 ± 10.1
Users of Alcohol (n [%]) 47 (56.6) 48 (58.5)
Smokers (n [%]) 24 (28.9) 22 (26.8)
KEQ-5D utility (mean ± SD) 0.94 ± 0.12 0.93 ± 0.10
KEQ-5D, Korean version of EuroQol 5 dimensions.
Table 2. Frequency and Severity of Symptom Recurrence at the End of Maintenance Treatment 
　Severity 　 Omeprazole 
n (%)
Rabeprazole
n (%)
P-value
Omeprazole Rabeprazole
P-value
Frequent rate (%) 95% CI Frequent rate (%) 95% CI
Heart burn No 78 (93.98) 75 (91.46) 0.713 17.78 (6.61-28.95) 23.81 (10.93-36.69) 0.488
Mild 4 (4.82) 5 (6.10) 　
Moderate 1 (1.2) 2 (2.44) 　
Regurgitation No 78 (93.98) 80 (97.56) 0.443 2.22 (0.00-6.53) 4.76 (0.00-11.20) 0.608
Mild 5 (6.02) 2 (2.44) 　
Moderate 0 (0.00) 0 (0.00) 　
Epigastric pain No 78 (93.98) 79 (96.34) 0.443 8.89 (0.57-17.20) 11.90 (2.11-21.70) 0.733
Mild 5 (6.02) 2 (2.44) 　
Moderate  0 (0.00) 1 (1.22) 　
between the 2 treatment groups in demographic variables, past 
medical histories and medications (Table 1). A total of 87 pa-
tients completed the trial through to the end of the 6-month 
maintenance treatment (45 who received omeprazole and 42 who 
received rabeprazole). 
Primary Efficacy Endpoint
For the ITT patients, symptom resolution rates observed at 
week 24 were 96.4% for the omeprazole 10 mg group and 95.1% 
for the rabeprazole 10 mg group. Symptom resolution rates for 
the two treatment groups did not differ significantly for any visit 
week (P ＞ 0.05). Results were similar for the per protocol 
population.
Secondary Efficacy Endpoint
Symptom frequency and severity
Table 2 summarizes the symptom frequency and severity at 
the last visit for both treatment groups. There were no significant 
differences between the treatment groups.
Recurrence rate of reflux esophagitis (endoscopy)
Four (6.7%) patients in the omeprazole group had a relapse 
and 4 (6.9%) patients in the rabeprazole group relapsed. No sig-
nificant difference existed between the treatment groups (P = 
1.000). Severity of recurred erosive esophagitis was also not sig-
nificantly different between the 2 groups (LA-A: 3 patients, 
LA-minimal change: 1 patient in the omeprazole group; LA-A: 
2 patients, LA-minimal change: 2 patients in the rabeprazole 
group).
KEQ-5D
At baseline, no significant difference in the mean utility 
scores existed between patients in the omeprazole and rabepra-
zole groups. After 24 weeks, the mean utility score for patients in 
the omeprazole group was 0.96 ± 0.10 compared with 0.96 ± 
0.08 in the rabeprazole group. Therefore, there was no statistical 
significant difference in improvement of QOL between the two 
groups after treatment.
Safety Evaluation
During the maintenance phase, a total of 143 adverse events 
were reported by 68 (41.21%) patients during the 24 weeks of 
treatment. Thirty-three of the 83 (39.75%) patients in the ome-
prazole group reported 72 events and 35 of the 82 (42.68%) pa-
tients in the rabeprazole group experienced 71 events. There was 
no significant difference between the treatments for any of the 
events considered to be possibly or probably related to the 
treatment. The same was true for the incidence of adverse events 
when categorized by body system. 
Cost Minimization Analysis
There was no significant difference in utility weight between 
2 treatments before and after maintenance treatments. Therefore, 
a cost minimization approach was considered to appropriate. The 
treatment that was associated with a lower cost of medicine was 
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 Table 3. Comparison of Direct, Indirect and Total Resource 
Costs Between the 2 Proton Pump Inhibitor Drugs 
Outpa-
tient cost
Drug 
cost
Drug
dispensing
Cost of
testing
Travel
cost
Total cost 
(won/6 mo)
Omeprazole 26,505 84,960 25,212 47,431 57,648 241,755
Rabeprazole 26,505 130,320 25,212 47,431 57,648 287,115
(As of 24 November 2011, 1 USD = 1,176.33 won)
Table 4. Proportion of All Relevant Variables Used in the Decision
Trees
Variables Proportion
Success of symptom control 0.965 (96.5%)
Failure of symptom control or relapse 0.035 (3.5%)
  Continuous maintenance with full dose of PPI 0.540 (54.4%)
  Continuous maintenance with half dose of PPI 0.120 (11.9%)
  On demand therapy (with full or half dose PPI ) 0.290 (28.7%)
  Surgery 0.050 (5.0%)
PPI, proton pump inhibitor.omeprazole 10 mg of 84,940 won at 6 months compared with 
130,320 won (as of 24 November 2011, 1 USD = 1,176.33 
won) for rabeprazole 10 mg at 6 months. The same difference 
was obtained with total costs, and PPI drug costs accounted for 
46.1% of the total direct costs (Table 3). Omeprazole was the less 
costly option for the maintenance treatment of GERD compared 
with rabeprazole.
Sensitivity Analysis 
Figure 2 depicts a decision tree to illustrate the possible man-
agement modalities after 6 months maintenance treatment of 
GERD. Baselines of relevant treatment plans are shown in Table 
4 with recurrence rates of GERD after 6 months maintenance 
treatment and the proportion of subsequent treatment modalities. 
The total annual expense of treatment with omeprazole is 
249,540 won and treatment with rabeprazole costs 295,781 won. 
This result demonstrates that rabeprazole will cost 46,241 won 
more than omeprazole for annual GERD treatment and it is con-
sistent with the results of this study. As a result, omeprazole 
emerges as a preferred treatment option for GERD.
Discussion
Long-term management of GERD with or without esoph-
agitis has become important since reflux symptoms have an ad-
verse impact on health-related QOL. Several studies have al-
ready demonstrated that full dose PPI is effective in the main-
tenance treatment of GERD.4,24 However, maintenance therapy 
using half dose PPI has not been fully evaluated, and fur-
thermore, comparative studies on the therapeutic and cost effec-
tiveness of half dose PPIs are relatively rare.
The present study has demonstrated that omeprazole 10 mg 
once daily and rabeprazole 10 mg once daily had similar efficacy 
and safety, but omeprazole 10 mg had higher cost effectiveness 
than rabeprazole 10 mg in preventing the relapse of erosive 
esophagitis and reflux symptoms during 6 months of treatment. 
This result is not consistent with the findings of other studies. 
Previous studies have suggested that Rabeprazole 10 mg once a 
day was equivalent to omeprazole 20 mg once a day in preventing 
recurrence of erosive GERD,15,25 and rabeprazole 10 mg pro-
vides more rapid acid inhibition compared with omeprazole 10 
mg.26 Although successful acid suppression affects both the 
speed and degree of symptom relief and mucosal healing27,28 ra-
beprazole has a greater potency than omeprazole when compared 
on a milligram basis.29 However omeprazole 20 mg is equivalent 
to rabeprazole 20 mg in healing reflux esophagitis and in the 
maintenance therapy of reflux esophagitis,30 but there has been no 
direct comparison of the effectiveness of omeprazole 10 mg and 
rabeprazole 10 mg in the maintenance of erosive esophagitis up 
until this current study. The findings of the present study suggest 
that omeprazole 10 mg once daily is at least as effective as rabe-
prazole 10 mg in long-term maintenance therapy in LA grade A 
or B erosive esophagitis.
Another aim of this study was to assess the difference in total 
cost of maintenance treatments between omeprazole 10 mg and 
rabeprazole 10 mg. Because using a PPI on demand and less of-
ten than daily is not as effective as continuous therapy for main-
taining healing and symptom resolution,31 most patients with 
GERD need long-term continuous management and this can 
cause a significant economic burden. In the economic evaluation, 
we need to take into account that the costs for management of 
GERD are dependent on various practice patterns or treatment 
pathways in different countries and health care systems. In Korea, 
outpatient costs and drug dispensing costs are generally very low. 
This means that the main element of expense in management of 
GERD is cost of the medicine. In fact, in this study, PPI medi-
cine cost accounted for 46% of the total cost and the difference of 
cost between the 2 drugs (the price of one omeprazole 10 mg tab-
let is 472 won and the cost of one rabeprazole tablet is 724 won) 
can explain the difference in total costs in the management of 
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GERD between the 2 groups. To conclude, omeprazole was the 
less costly option for the maintenance treatment of GERD com-
pared with rabeprazole.
Symptomatic and endoscopic remission rates at 6 months 
(96.4% for the omeprazole group and 93.3% for the rabeprazole 
group) of this study are relatively high compared with the rates 
observed in studies of esomeprazole 20 mg (83%)32 and lansopra-
zole 15 mg (74%).33 A possible explanation for this difference is 
that patients with LA grades C and D were excluded from this 
study. This may have increased the endoscopic remission rate at 
the end of 6 months. However, exclusion of patients with severe 
esophagitis might not have effect on symptom severity of GERD 
patients, since symptom severity is a poor predictor for the grade 
of esophagitis.34,35 A second possibility is that we analyzed symp-
tomatic and endoscopic remission rates separately as a primary 
and second end point. Actually, if we change the definition of the 
primary end point as the proportion of patients in endoscopic plus 
symptomatic remission, the response rate of the omeprazole group 
is decreased to 91.6% and the response rate of the rabeprazole 
group is decreased to 90.2%.
One possible limitation of our study was that the Helicobacter 
pylori test was not used in our study. Several reports have sug-
gested that H. pylori positive patients were less likely to have 
GERD, and when present, the severity of esophagitis was de-
creased compared to those who were H. pylori negative.36,37 
However, although admitting that a strong negative association 
exists between reflux esophagitis and H. pylori, GERD symp-
toms had no association with H. pylori status at baseline and fol-
low-up after H. pylori eradication.38,39 Therefore, H. pylori in-
fection itself might not have a significant effect on the result of 
this study. 
It is interesting that although a high correlation between the 
absence of symptoms and maintenance of the healing of EE was 
found in a study of maintenance treatment with once daily esome-
prazole for 6 months,8 there was no concurrence between the ab-
sence of reflux symptoms and maintenance of healing during 
maintenance therapy in this study. This finding was not in line 
with the report that the control of symptoms was a reliable in-
dicator for maintained healing of esophagitis.24 However, mu-
cosal erythema at endoscopy correlates poorly with reflux symp-
toms,40 and also the severity of GERD symptoms does not pre-
dict disease severity in patients with erosive esophagitis.41 There-
fore, symptom relief alone may not be the basis for the resolution 
of erosive esophagitis.
In conclusion, treatment with omeprazole 10 mg once daily 
in patients with Grade A or B erosive esophagitis is as effective as 
rabeprazole 10 mg once daily in relieving symptoms, and well tol-
erated, and is superior to rabeprazole 10 mg once daily in terms of 
cost effectiveness.
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